Nextech Invest, a venture capital and private equity firm, led a $85m Series A round in Ambagon Therapeutics, a biotechnology company, with participation from RA Capital Management, Droia Ventures, Inkef Capital, AbbVie Ventures, MRL Ventures Fund, Mission BioCapital, and Surveyor Capital. “Our deep understanding of 14-3-3 biology has broad applications for drug discovery as it opens up disordered protein regions as therapeutic targets. Combined with our proprietary structural insights, curated chemical library, and bespoke drug discovery tools, our experienced drug development team is well placed to bring forward new medicines addressing previously undruggable targets,” Scott Clarke, Ambagon Chief Executive Officer.